HKG: 2696

Explore the latest insights on HKG: 2696 and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of HKG: 2696’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Qingdao Baheal Pharmaceutical Co., Ltd. (SHE: 301015) announced that the outbound investment and related‑party transaction of its wholly‑owned subsidiary, Baheal Health, has been completed and closed. Under the transaction, Baheal…

Bio-Link Capital Completes Strategic Investment in TYK Medicines – Doubling Down on Bispecific, Trispecific and ADC Antibody Platforms

Bio-Link Capital Completes Strategic Investment in TYK Medicines – Doubling Down on Bispecific, Trispecific and ADC Antibody Platforms

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Henlius Biotech’s HLX26 and HaiSiZhuang Combo for NSCLC Gets NMPA Phase II Approval

Company

Henlius Reports 97.2% YOY Revenue Growth in Q1 2023, Highlighted by Strong Sales of Hanquyou and HaiSiZhuang

Company

Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization

CompanyDrug

Henlius Biotech’s Serplulimab Accepted for EMA Review for ES-SCLC Treatment

CompanyDrug

Henlius’ OX40 Monoclonal Antibody HLX51 Gains NMPA Approval for Phase I Clinical Study

CompanyDrug

Henlius Begins Phase I Trial for Biosimilar HLX15 Targeting Multiple Myeloma

CompanyDeals

Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience

CompanyDrug

Henlius’ PD-1 Inhibitor HanSiZhuang Approved for First-Line SCLC Indication

Show More